Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation

References

• FerlayJSteliarova-FoucherELortet-TieulentJCancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012Eur J Cancer20134961374140323485231
   PubMed Web of Science ®Google Scholar
• Cancer Research UKProstate cancer statistics [homepage on the Internet]London, UKCancer Research UK Available from: http://info.cancerresearchuk.org/cancerstats/types/prostateAccessed April 3, 2013
   Google Scholar
• BrayFRenJSMasuyerEFerlayJGlobal estimates of cancer prevalence for 27 sites in the adult population in 2008Int J Cancer201313251133114522752881
   PubMed Web of Science ®Google Scholar
• International Agency for Research on CancerGLOBOCAN 2008, WHO Europe Region Available from: http://globocan.iarc.fr/Accessed April 3, 2013
   Google Scholar
• RyanCJElkinEPSmallEJDuchaneJCarrollPReduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSUREUrol Oncol200624539640216962488
   PubMed Web of Science ®Google Scholar
• SchröderFHHugossonJCarlssonSScreening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)Eur Urol201262574575222704366
   PubMed Web of Science ®Google Scholar
• WardJFMoulJWBiochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancerCurr Opin Urol200515318118615815195
   PubMed Web of Science ®Google Scholar
• KlotzLHPSA recurrence: definitions, PSA kinetics, and identifying patients at riskCan J Urol200613Suppl 2434716672128
   PubMedGoogle Scholar
• HeidenreichABastianPJBellmuntJGuidelines on Prostate CancerArnhem, the NetherlandsEuropean Association of Urology2012 Available from: http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdfAccessed April 3, 2013
   Google Scholar
• McleodDGHormonal therapy: historical perspective to future directionsUrology2003612 Suppl 13712667881
   PubMed Web of Science ®Google Scholar
• WassersugRJJohnsonTWModern-day eunuchs: motivations for and consequences of contemporary castrationPerspect Biol Med200750454455617951888
   PubMed Web of Science ®Google Scholar
• SeidenfeldJSamsonDJAronsonNRelative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancerEvid Rep Technol Assess (Summ)19994ix1246I1I36 passim11098244
   PubMedGoogle Scholar
• Fujikawa K, Awakura Y, Okabe T, Watanabe R, Nishimura S. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer.]Nippon Hinyokika Gakkai Zasshi2003944503511 Japanese12795165
   PubMedGoogle Scholar
• BollaMColletteLBlankLLong-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialLancet2002360932710310612126818
   PubMed Web of Science ®Google Scholar
• MiyamotoHMessingEMChangCAndrogen deprivation therapy for prostate cancer: current status and future prospectsProstate200461433235315389811
   PubMed Web of Science ®Google Scholar
• YouDJeongIGKimSWImpacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter studyScand J Urol Nephrol201044639940520707648
   PubMed Web of Science ®Google Scholar
• BergesRNew trends in managing the prostate cancer patientEuropean Urology Supplements2008713758764
   Web of Science ®Google Scholar
• NairBWiltTMacDonaldRRutksIEarly versus deferred androgen suppression in the treatment of advanced prostatic cancerCochrane Database Syst Rev20021CD00350611869665
   PubMedGoogle Scholar
• MottetNBellmuntJBollaMEAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol201159457258321315502
   PubMed Web of Science ®Google Scholar
• WiltTJMacDonaldRRutksIShamliyanTATaylorBCKaneRLSystematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancerAnn Intern Med2008148643544818252677
   PubMed Web of Science ®Google Scholar
• TanakaNFujimotoKHirayamaAThe primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-Oncological research group registrationBMC Urol201111621524283
   PubMed Web of Science ®Google Scholar
• UtomoNBMochtarCAUmbasRPrimary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factorsActa Med Indones2012441101522451179
   PubMedGoogle Scholar
• ToguchiHFormulation study of leuprorelin acetate to improve clinical performanceClin Ther199214Suppl A1211301606592
   PubMed Web of Science ®Google Scholar
• ChuFMJaysonMDineenMKPerezRHarkawayRTylerRCA clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol200216831199120312187267
   PubMed Web of Science ®Google Scholar
• Perez-MarreroRTylerRCA subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancerExpert Opin Pharmacother20045244745714996640
   PubMed Web of Science ®Google Scholar
• SharifRSolowayMClinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study GroupJ Urol1990143168712104638
   PubMed Web of Science ®Google Scholar
• LeeMBrownellerRWuZJungARatanawongCSharifiRTherapeutic effects of leuprorelin microspheres in prostate cancerAdv Drug Deliv Rev199728112113810837568
   PubMed Web of Science ®Google Scholar
• PeritiPMazzeiTMiniEClinical pharmacokinetics of depot leuprorelinClin Pharmacokinet200241748550412083977
   PubMed Web of Science ®Google Scholar
• AbouelfadelZCrawfordEDLeuprorelin depot injection: patient considerations in the management of prostatic cancerTher Clin Risk Manag20084251352618728847
   PubMedGoogle Scholar
• OuzaidIRouprêtM[The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the ‘ELIRE’ observational study.]Prog Urol20112112866874 French22035913
   PubMed Web of Science ®Google Scholar
• CrawfordEDPhillipsJMSix-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfortCancer Manag Res2011320120921847353
   PubMedGoogle Scholar
• TunnUWA 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patientsBMC Urol2011111521801354
   PubMed Web of Science ®Google Scholar
• AlloulKSauriolLLafortuneLMeta-analysis and economic evaluation of LHRH agonists’ depot formulations in advanced prostatic carcinomaCan J Urol19985358559411305958
   PubMedGoogle Scholar
• WeightCJKleinEAJonesJSAndrogen deprivation falls as orchiectomy rates rise after changes in reimbursement in the US Medicare populationCancer2008112102195220118393326
   PubMed Web of Science ®Google Scholar
• OdeyemiIAOBergesRBolodeokuJEconomic impact of different preparations of leuprolide acetate in the management of advanced prostate cancerJ Med Econ2007102135146
   Google Scholar
• HeynsCFSimoninMPGrosgurinPSchallRPorchetHCSouth African Triptorelin Study GroupComparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancerBJU Int200392322623112887472
   PubMed Web of Science ®Google Scholar
• Perez-MarrenoRChuFMGleasonDLoizidesEWachsBTylerRCA six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerClin Ther200224111902191412501882
   PubMed Web of Science ®Google Scholar
• MarbergerMKaisaryAVShoreNDEffectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter studyClin Ther201032474475720435244
   PubMed Web of Science ®Google Scholar
• OefeleinMGTime to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study considerationJ Urol19981605168516889783932
   PubMed Web of Science ®Google Scholar
• OefeleinMGSerum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessmentUrology199954469469910510930
   PubMed Web of Science ®Google Scholar
• OefeleinMGCornumRFailure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithmJ Urol20001643 Pt 172672910953134
   PubMed Web of Science ®Google Scholar
• CrawfordEDSartorOChuFPerezRKarlinGGarrettJSA 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol2006175253353616406989
   PubMed Web of Science ®Google Scholar
• SpitzAYoungJMLarsenLMattia-GoldbergCDonnellyJChwaliszKEfficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancerProstate Cancer Prostatic Dis2012151939922025196
   PubMed Web of Science ®Google Scholar
• FujiiYYoneseJKawakamiSYamamotoSOkuboYFukuiIEquivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancerBJU Int200810191096110018190637
   PubMed Web of Science ®Google Scholar
• YriOEBjoroTFossaSDFailure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancerEur Urol20064915458 discussion 5816314038
   PubMed Web of Science ®Google Scholar
• ImamuraTYasunagaHEconomic evaluation of prostate cancer screening with prostate-specific antigenInt J Urol200815428528818380812
   PubMed Web of Science ®Google Scholar
• HuntTLLuceBRPageMJPokrzywinskiRWillingness to pay for cancer preventionPharmacoeconomics200927429931219485426
   PubMed Web of Science ®Google Scholar
• MolinierLBauvinECombescureCMethodological considerations in cost of prostate cancer studies: a systematic reviewValue Health200811587888518494749
   PubMed Web of Science ®Google Scholar
• RoehrbornCGAlbertsenPStokesMEBlackLBenedictAFirst-year costs of treating prostate cancer: estimates from SEER-Medicare dataProstate Cancer Prostatic Dis200912435536019468284
   PubMed Web of Science ®Google Scholar
• KonskiAShermanEKrahnMEconomic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10)Int J Radiat Oncol Biol Phys200563378879416109464
   PubMed Web of Science ®Google Scholar
• NeymarkNAdriaenssenIGorliaTCaleoSBollaMBrochonDCost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysisEur J Cancer200137141768177411549430
   PubMed Web of Science ®Google Scholar
• BuronCLe VuBCossetJMBrachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic studyInt J Radiat Oncol Biol Phys200767381282217293235
   PubMed Web of Science ®Google Scholar
• RohdeVGrabeinKWeidnerWWasemJHesselFThe German HTA report: orchiectomy versus LH-RH analogues in the treatment of advanced prostate carcinoma: are there any consequences for the daily health service?Aktuelle Urol200839644845518979400
   PubMed Web of Science ®Google Scholar
• TuriniMRedaelliAGramegnaPRadiceDQuality of life and economic considerations in the management of prostate cancerPharmacoeconomics200321852754112751912
   PubMed Web of Science ®Google Scholar
• RutqvistLEWilkingNAnalogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancerBr J Cancer19926569279291616866
   PubMed Web of Science ®Google Scholar
• BayoumiAMBrownADGarberAMCost-effectiveness of androgen suppression therapies in advanced prostate cancerJ Natl Cancer Inst200092211731173911058616
   PubMedGoogle Scholar
• LazzaroCBartolettiRGuazzoniGQuABIOS Study GroupEconomic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS)Arch Ital Urol Androl200779310410718041359
   PubMedGoogle Scholar
• MavranezouliILARC Guideline Development GroupThe cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence clinical practice guidelineHum Reprod20082361338134518372257
   PubMed Web of Science ®Google Scholar
• PerachinoMMonferratoCFerrarisVAndrogen deprivation therapy (ADT) and testosterone (T) in prostate cancer patients: The lower is really the betterEur Urol Suppl200873204
   Web of Science ®Google Scholar
• SeidenfeldJSamsonDJHasselbladVSingle-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysisAnn Intern Med2000132756657710744594
   PubMed Web of Science ®Google Scholar
• KaisaryAVTyrrellCJPeelingWBGriffithsKComparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinomaBr J Urol19916755025081828183
   PubMedGoogle Scholar
• RøhlHFBeukeHPEffect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancerScand J Urol Nephrol199226111141631501
   PubMed Web of Science ®Google Scholar
• McLeodDZinnerNTomeraKAbarelix Study GroupA phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerUrology200158575676111711355
   PubMed Web of Science ®Google Scholar
• KawakamiJMoralesAA comprehensive evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists [abstract]J Urol2002176288
   Google Scholar
• EsquenaSAbascalJMTrillaEMoroteJFailure of luteinising hormone releasing hormone agonist therapy to achieve castration. Does it exist [abstract]?European Urology Supplements20043257
   Google Scholar
• TombalBBergesRHow good do current LHRH agonists control testosterone? Can this be improved with Eligardd®?European Urology Supplements2005483036
   Web of Science ®Google Scholar
• TombalBAppropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone?European Urology Supplements2005451419
   Web of Science ®Google Scholar
• KhanMSO’BrienAAn evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostateUrol Int199860133409519419
   PubMed Web of Science ®Google Scholar
• SarosdyMFSchellhammerPFSolowayMSEndocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancerBJU Int199983780180610368200
   PubMed Web of Science ®Google Scholar
• SharifiRBrownellerRLeuprolide Study GroupSerum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancerJ Urol200216831001100412187208
   PubMed Web of Science ®Google Scholar
• MoroteJEsquenaSAbascalJMFailure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancerUrol Int200677213513816888418
   PubMed Web of Science ®Google Scholar
• MoroteJPlanasJRaventosCXThe serum testosterone castration level with clinical relevance [abstract]European Urology Supplements2007629
   Web of Science ®Google Scholar
• ZlottaADebruyneFMJExpert opinion on optimal testosterone control in prostate cancerEuropean Urology Supplements2005483741
   Web of Science ®Google Scholar
• TombalBThe importance of testosterone control in prostate cancerEuropean Urology Supplements2007615834839
   Web of Science ®Google Scholar
• TeutonicoDMontanariSPonchelGLeuprolide acetate: pharmaceutical use and delivery potentialsExpert Opin Drug Deliv20129334335422335366
   PubMed Web of Science ®Google Scholar
• DiasSilva ÉFerreiraUMatheusWGoserelin versus leuprolide in the chemical castration of patients with prostate cancerInt Urol Nephrol20124441039104422315155
   PubMed Web of Science ®Google Scholar
• NovaraGGalfanoASeccoSFicarraVArtibaniWImpact of surgical and medical castration on serum testosterone level in prostate cancer patientsUrol Int200982324925519440008
   PubMed Web of Science ®Google Scholar
• FuldeoreMJBrookRASmeedingJDabbousOHLeuprolide acetate persistence varies by age in patients with prostate cancer [abstract]Value Health2008113A73
   Web of Science ®Google Scholar
• PayneHAEdwardsSJEfficacy of leuprorelin 3.75 mg compared to 7.5 mg in the treatment of prostate cancer: systematic review and meta-analysis [abstract]Value Health2008116A459
   Web of Science ®Google Scholar
• IannazzoSPradelliLCarsiMPerachinoMCost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in ItalyValue Health2011141808921211489
   PubMed Web of Science ®Google Scholar
• SethiRSanfilippoNSix-month depot formulation of leuprorelin acetate in the treatment of prostate cancerClin Interv Aging2009425926719554097
   PubMed Web of Science ®Google Scholar